We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
내부자 거래(Form 4) 신고가 제출되었습니다.
내부자 거래(Form 4) 신고가 제출되었습니다.
내부자 거래(Form 4) 신고가 제출되었습니다.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 21. | 장 마감 후 (AMC) | $1.83 | — | — | $6.09B | — | 예정 |
| FY2026 Q1 | 2026. 04. 21. | 시각 미정 | — | $1.32 | — | — | $5.74B | 보고됨 |
| FY2025 Q3 | 2024. 09. 27. | 시각 미정 | — | $3.8 | — | — | $17.34B |
Consensus PT $245.39 · 23 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | Citigroup | — | 투자의견 하향 | Buy → Neutral | — | Citigroup: Buy → Neutral |
| 2026. 04. 24. | Morgan Stanley | — | 의견 유지 | Overweight → Overweight | — | Morgan Stanley: Overweight |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
내부자 거래(Form 4) 신고가 제출되었습니다.
내부자 거래(Form 4) 신고가 제출되었습니다.
내부자 거래(Form 4) 신고가 제출되었습니다.
내부자 거래(Form 4) 신고가 제출되었습니다.
내부자 거래(Form 4) 신고가 제출되었습니다.
내부자 거래(Form 4) 신고가 제출되었습니다.
| FY2025 Q2 | 2024. 06. 28. | 시각 미정 | — | $2.68 | — | — | $11.54B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Stored first · Google News · Yahoo Finance (English)